Investor Relations

Corporate Profile

To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.

Data Provided by Refinitiv. Minimum 15 minutes delayed.